BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 18299683)

  • 1. Proteinuria: natural course, prognostic implications and therapeutic considerations.
    Sarafidis PA
    Minerva Med; 2007 Dec; 98(6):693-711. PubMed ID: 18299683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [What do large clinical trials learn us about cardiovascular and renal prevention in patients with type 2 diabetes mellitus and hypertension?].
    Dussol B; Berland Y
    Nephrol Ther; 2006 May; 2(2):51-74. PubMed ID: 16895717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microalbuminuria in essential hypertension.
    Crippa G
    J Hum Hypertens; 2002 Mar; 16 Suppl 1():S74-7. PubMed ID: 11986900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microalbuminuria and hypertension.
    Reboldi G; Gentile G; Angeli F; Verdecchia P
    Minerva Med; 2005 Aug; 96(4):261-75. PubMed ID: 16179893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Microalbuminuria is an early marker for increased morbidity and mortality].
    Bramlage P; Wittchen HU; Pittrow D; Dikow R; Kirch W; Lehnert H; Ritz E
    Fortschr Med Orig; 2003 Feb; 121 Suppl 1():28-32. PubMed ID: 14732947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Microalbuminuria: theoretical bases and new applications].
    Airoldi G; Campanini M
    Recenti Prog Med; 1993 Mar; 84(3):210-24. PubMed ID: 8465103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time to abandon microalbuminuria?
    Ruggenenti P; Remuzzi G
    Kidney Int; 2006 Oct; 70(7):1214-22. PubMed ID: 16871239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of reducing microalbuminuria in patients with type 2 diabetes mellitus.
    Araki S; Haneda M; Koya D; Kashiwagi A; Uzu T; Kikkawa R
    Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S54-8. PubMed ID: 18947896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of hypertension in patients with diabetes.
    Sowers JR
    Arch Intern Med; 2004 Sep; 164(17):1850-7. PubMed ID: 15451759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minor abnormalities of renal function: a situation requiring integrated management of cardiovascular risk.
    Segura J; Ruilope LM
    Fundam Clin Pharmacol; 2005 Aug; 19(4):429-37. PubMed ID: 16011729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Microalbuminuria, hypertension, and cardiovascular risk].
    Deferrari G; Pontremoli R
    Cardiologia; 1994 Dec; 39(12 Suppl 1):159-62. PubMed ID: 7634260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic kidney disease and global cardiovascular risk in essential hypertension.
    Segura J; Campo C; Ruilope LM
    Minerva Med; 2004 Oct; 95(5):375-83. PubMed ID: 15467513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in diabetic nephropathy.
    Marshall SM
    Postgrad Med J; 2004 Nov; 80(949):624-33. PubMed ID: 15537844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertension in diabetes mellitus.
    Hasslacher C; Ritz E; Tschöpe W; Gallasch G; Mann JF
    Kidney Int Suppl; 1988 Sep; 25():S133-7. PubMed ID: 3184604
    [No Abstract]   [Full Text] [Related]  

  • 15. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients.
    Steinke JM; Mauer M;
    Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():958-63. PubMed ID: 18806710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microalbuminuria as an early marker for cardiovascular disease.
    de Zeeuw D; Parving HH; Henning RH
    J Am Soc Nephrol; 2006 Aug; 17(8):2100-5. PubMed ID: 16825327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes.
    Ibsen H; Olsen MH; Wachtell K; Borch-Johnsen K; Lindholm LH; Mogensen CE
    J Nephrol; 2008; 21(4):566-9. PubMed ID: 18651547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic kidney disease and cardiovascular risk in hypertensive type 2 diabetics: a primary care perspective.
    Ravera M; Noberasco G; Re M; Filippi A; Gallina AM; Weiss U; Cannavò R; Ravera G; Cricelli C; Deferrari G
    Nephrol Dial Transplant; 2009 May; 24(5):1528-33. PubMed ID: 19073656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microalbuminuria among type-2 diabetes mellitus patients in Pokhara, Nepal.
    Sigdel M; Rajbhandari N; Basnet S; Nagila A; Basnet P; Tamrakar BK
    Nepal Med Coll J; 2008 Dec; 10(4):242-5. PubMed ID: 19558062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.